We would love to hear your thoughts about our site and services, please take our survey here.
and rightly so. This is not a forum for political rants with thinly disguised expletives, it is a forum for discussing the prospects for Sareum. On the whole this forum is one of the better ones in terms of quality analysis and opinion. Let's keep it that way.
The prospects for Sareum look very encouraging to me with news possible on CHK1, TYK2, FLT3 and the company more broadly. I think we will see news possibly throughout Q1 and Q2 on at least 2 of the compounds. I remain of the view that the cleanest exit for Tim and John and entry for a Pharma is via a takeout. We shall see. Happy New Year all.
Not strictly true if you take account of shares in issue which have more than doubled over the past 10 years. That is to say in 2010 terms Sareum's share price on Friday was actually equivalent to 3.15p then and the spike to 3p the other week was 7.12p in 2010 terms.
A scenario which remains firmly and obviously on the table for Sareum. I'm a long enough holder to remember this RNS from Sareum on 4 March 2005:
"The Board of Sareum notes recent speculation and confirms that it is in discussions with a party that may or may not lead to an offer being made for the Company.
A further announcement will be made when appropriate."
Followed by this on April 25:
"On 4 March 2005, Sareum announced that it was in discussions with a party that may or may not lead to an offer being made for the Company. The Company announces that these discussions have terminated.
The Sareum directors continue to work to develop the Company's structure-based drug discovery and services business and remain confident about its future prospects."
Fifteen and a half years on and Tim is no longer 45, John no longer 38. For prospective acquirers, Sareum represents an almost unique opportunity. No plant, just two employees to assimilate (or retain) and company which aside from a few contracts is almost deliverable on a memory stick (intellectual property). A cleaner target for a take over you could hardly imagine.
The easiest and cleanest out for us all especially for Tim and John.
DYOR
S
I understand that the efficacy data will be published by Dec 4 and unlike Pfizer and Moderna it will importantly likely contain "effect on transmission" data, something the others have not been collecting data on. The Oxford team have been swabbing every PIII participant at least weekly and therefore could deliver good news on 2 fronts. The Oxford vaccine is the most scalable, among the least expensive and easiest to transport and store. Not surprising 2.4bn pre-orders have been made. For Sareum we should hope that the impact will be further reduced from the Pfizer and Moderna impacts. I think our destiny lies in different areas. S
Wouldn't it be something if Tim and John hit upon 3 key targets CHK1, FLT and TYK. That would surely be almost unprecedented in the world of biotech firms. When they left Millennium to form Sareum back in 2004 they seemed convinced CHK1 was going to be a major cancer kinase target. Fifteen years on and they may be onto the cusp of realising that dream. And with SKIL they identified FLT and TYK as likely key drug targets. amazing to think all three could see major progression in the next 6 months. S
Well that's another good point. FLT/Aurora China not mentioned today. Perhaps because they are aware the milestone is close at hand. In my opinion SAR will close higher today as people realise this RNS is actually progression.
I'm saying they have no control over CHK1 licensing negotiations and have not had since as far back as 2007 when CRT and ICR held the majority stake. this is in contrast to TYK/JAK which as Mitchell states today in this RNS is wholly owned by Sareum. It is those negotiations not the ones renegotiated today that we should all be focussing on. IT is TYK/JAK where we need Sareum to be tough negotiators. If you are nervous you have a very easy choice. But do please understand the structure of the company and the products it owns or only partly owns. S
but this GOOD news. It finally clears the CHK1 impasse and Tim clearly states "In parallel, we continue to invest our own cash resources to progress our exciting wholly owned TYK2/JAK1 inhibitor programmes towards the clinic as planned."
There is no precedent with this as someone said as it was not Sareum or Tim Mitchell negotiating with Sierra. Next news will be on TYK/JAK and I'd wager before year end. DYOR. S